Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, 27 September 2023 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company"), a pioneer in the development of innovative vaccines for a healthier world, today announced that Dr. Mattis Ranthe, Chief Medical Officer, and Dr. Mette Thorn, Senior Vice President of Preclinical Development, are stepping down from their positions in the Company following the future strategic focus on ExpreS2ion's exploratory vaccine pipeline and technology platforms, as announced in press release of 17 August 2023. Dr. Ranthe will continue supporting the Company through the end of 2023 to ensure the transition of his responsibilities. Dr. Thorn's last day is 29 September 2023, and her responsibilities will be covered by internal resources.
"Over the last two years, Dr. Ranthe and Dr. Thorn have played key roles in the development of ES2B-C001," comments Bent Frandsen, Chief Executive Officer. "I extend my gratitude to them for their contributions to the Company, our investors, and the individuals whose well-being we aspire to enhance."
"I am proud to have been a member of the leadership team that readied ExpreS[2]ion for clinical development and formed world-class scientific advisory boards. With the clinical development plan for the ES2B-C001 therapeutic breast cancer vaccine so mature, it will be exciting to follow the next steps for this promising asset. I sincerely hope ExpreS[2]ion will be successful in bringing this vaccine to cancer patients." says Dr. Mattis Ranthe, Chief Medical Officer.
"Through the adjustment of our headcount and the pursuit of other strategic pathways for the ES2B-C001 breast cancer vaccine program, the Company extends its financial runway beyond 2024, as previously announced," reiterates Bent Frandsen, Chief Executive Officer. "Our strategic focus remains on optimizing our R&D initiatives and development pipeline by harnessing the capabilities of our Phase III clinically validated ExpreS2[TM] platform. This approach enables us to prioritize the development of innovative vaccines with a faster and more cost-efficient path to value generation."
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
This press release constitutes inside information that ExpreS2ion Biotech Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out below, at the time stated by the Company's news distributor, Cision, at the publication of this press release.